Butylphthalide ameliorates experimental autoimmune encephalomyelitis by suppressing PGAM5-induced necroptosis and...

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic central nervous system autoimmune disorder with unknown etiology.
• Experimental autoimmune encephalomyelitis (EAE) is a key animal model for studying MS pathogenesis and therapeutic interventions.

Purpose of the Study:

• To investigate the therapeutic potential of Dl-3-n-butylphthalide (NBP) in experimental autoimmune encephalomyelitis (EAE).
• To elucidate the role of PGAM5 in NBP's protective effects against EAE.

Main Methods:

• Administration of NBP to EAE-induced mice.
• Analysis of spinal cord tissues for inflammatory factors and necroptosis-associated genes (PGAM5).
• In vitro studies involving microglia, PGAM5 manipulation (silencing/overexpression), and TNFα plus zVAD-fmk stimulation.

Main Results:

• NBP treatment prevented EAE development and reduced spinal cord inflammation and necroptosis-associated genes, including PGAM5.
• Silencing PGAM5 in spinal cords ameliorated EAE severity, while its re-expression counteracted NBP's protective effects.
• NBP and PGAM5 silencing inhibited necroptosis and inflammation in microglia; PGAM5 overexpression reversed NBP's suppressive effects.

Conclusions:

• Dl-3-n-butylphthalide (NBP) attenuates EAE progression by suppressing PGAM5-induced necroptosis and inflammation in microglia.
• NBP represents a promising therapeutic strategy for autoimmune diseases by targeting the PGAM5 pathway.